Dr. Moss is now offering the Bredesen ReCODE Protocol™ for preventing and reversing cognitive decline and dementia
One of the biggest concerns expressed by my patients is about cognitive decline and their risk for Alzheimer’s disease, the most common form of dementia. I have great news for all of you. In one of the most important books written in years, The End of Alzheimers, Dr. Dale Bredesen presents a program, based on solid science and clinical studies, that has actually reversed early dementia and prevented any progression for those with minimal cognitive decline.
Through extensive research he has identified 36 factors that contribute to the abnormal production of beta amyloid and tau proteins, the underlying abnormality in Alzheimer’s disease. His approach to reversal and prevention includes many of the core aspects that have been part of my practice for decades: detoxifying toxins like lead and mercury, optimizing hormones through bio-identical therapies, identifying and treating nutritional deficiencies and focusing on diet, stress reduction and exercise.
To make the this program available to all of you, I have taken the Bredesen physician training course and am a Certified Physician in the Bredesen Protocol™ the organization he has created to support patients in recovery and prevention. I suggest that any person who has a family history of dementia, signs of memory issues, or genetic risks such as the ApoE4 gene, undertake the Cognoscopy ™ evaluation to assess risks for memory loss. This entails blood tests, assessment of heavy metal toxicity and other toxin exposures such as molds, cognitive testing (MoCA test) and if needed an MRI to assess brain volumetrics.
This approach is a game changer in the fight against Alzheimer’s, which will effect over 10 million Americans in the next decade and is a tremendous stressor on families and caretakers. If you want to start a prevention program or work on reversing some early symptoms call the office to set up an appointment and go to MPICognition.com to learn more about this program.
The following is an excerpt from the MPI Cognition™ website:
Of the 318 million Americans currently living, 45 million will develop Alzheimer’s disease during their lifetimes if we do not do something to prevent and reverse cognitive decline. Many others will suffer from vascular dementia or Lewy body dementia or other forms of dementia. Loss of mental faculties has become the #1 concern of aging Americans.
Medicine is undergoing a radical transformation, from 20th-century medicine to 21st-century medicine: 20th-century medicine uses small data sets—like looking at sodium and potassium but not the genome or metabolome or epigenome—to attempt to diagnose very complex illnesses in very complicated organisms—human beings. 20th-century medicine makes a diagnosis of what—Alzheimer’s or cardiovascular disease or hypertension—without understanding why. 20th-century medicine uses a one-size-fits-all, monotherapeutic approach, and has been largely unsuccessful in treating chronic illnesses such as Alzheimer’s disease, other neurodegenerative conditions, cancer, and cerebrovascular disease.
21st-century medicine is completely different: larger data sets are used to identify network changes that characterize chronic illnesses, revealing the “why” for each person—this is the etiodiagnosis. Prevention and early symptomatic approaches are emphasized. Addressing the cause of each condition in a comprehensive and personalized, programmatic way leads to improved outcomes, and each program is repeatedly optimized over time, to ensure sustained improvement.
Such an approach was used to bring about the first reversal of cognitive decline in patients with early Alzheimer’s disease or its precursors, MCI (mild cognitive impairment) and SCI (subjective cognitive impairment), published in 2014 (Bredesen, Aging 2014). MPI Cognition was established to provide the research, support, and information to make this approach available to all. We have identified multiple subtypes of Alzheimer’s disease using the extensive metabolic profiling of 21st-century medicine (Bredesen, Aging 2015), identified new and previously unrecognized causes of Alzheimer’s disease (Aging 2016), and developed a continuously evolving version of Dr. Bredesen’s original MEND program. We hope that this information, research, and support will be valuable to all in our shared goal of reducing the global burden of dementia.
The Protocol provides a comprehensive personalized program designed to improve cognition and reverse the cognitive decline of SCI, MCI, and early Alzheimer’s disease. Continued research and testing by Dr. Bredesen began by evolving MEND into The Bredesen Protocol, which has identified new and previously unrecognized causes of Alzheimer’s disease.
The ReCODE Report
The ReCODE Report is derived from the Bredesen Protocol, a comprehensive personalized program designed to improve cognition and reverse the cognitive decline of SCI (subjective cognitive impairment), MCI (mild cognitive impairment), and early Alzheimer’s disease. The ReCODE Report utilizes the protocol to inform and produce an optimal program to stop the progression of cognitive decline and begin improvement—the only effective program to date. This is a comprehensive program that optimizes many different metabolic, hormonal, and other parameters to enhance cognition and reverse cognitive decline.
For those who are without symptoms, it is important to be evaluated, identify risk factors, and address these to optimize cognition for decades to come. There is a straightforward and inexpensive program to do just that, with continued updates and evolution as research leads to iterative enhancements.
For those who have begun to demonstrate symptoms, including those with SCI (subjective cognitive impairment), MCI (mild cognitive impairment), and early Alzheimer’s disease, there is an optimal program to stop progression and begin improvement—the only effective program to date. This is a comprehensive program that optimizes many different metabolic parameters to enhance cognition and reverse cognitive decline.